JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

Anesth Analg 2008; 106:1101-1103
© 2008 International Anesthesia Research Society
doi: 10.1213/ane.0b013e31816794d9
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Bauer, C.
Right arrow Articles by Lehot, J.-J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bauer, C.
Right arrow Articles by Lehot, J.-J.
Related Collections
Right arrow Coagulation
Right arrow Complications
Right arrow Cardiovascular
Right arrow Monitoring (Cardiac)

CARDIOVASCULAR ANESTHESIOLOGY

Extracorporeal Membrane Oxygenation with Danaparoid Sodium After Massive Pulmonary Embolism

Christian Bauer, MD*§, Zuzana Vichova, MD*§, Patrick Ffrench, MD*{dagger}, Christiane Hercule, MD*, Olivier Jegaden, PhD*{ddagger}, Olivier Bastien, PhD*§, and Jean-Jacques Lehot, PhD*§

From *Université Claude Bernard Lyon 1, France; and {dagger}Hemostasis Laboratory, {ddagger}Department of Cardiovascular Surgery, and §Anesthesiology and Intensive Care Unit, Hospices Civils de Lyon, Hopital Cardiovasculaire et Pneumologique Louis Pradel, Bron, France.

Address correspondence to Christian Bauer, MD, Hospices Civils Lyon, Hopital Cardiovasculaire et Pneumologique Louis Pradel, Anesthesiology and Intensive Care Unit, Bron, F-69677, France. Address e-mail to christian.bauer{at}chu-lyon.fr.

Abstract

During extracorporeal membrane oxygenation, anticoagulation therapy is usually achieved with unfractionated heparin. We report on an extracorporeal membrane oxygenation with danaparoid sodium for a patient with severe respiratory failure due to massive pulmonary embolism and suspected type 2 heparin-induced thrombocytopenia. Danaparoid, a low molecular weight heparinoid, is an alternative to heparin for patients who develop type 2 heparin-induced thrombocytopenia. Danaparoid was given at 400 IU/h with an objective of antifactor Xa activity of 0.6–0.8 U/mL, which was monitored twice a day. No excessive bleeding or clotting of the circuit was noted. The patient was weaned from extracorporeal membrane oxygenation after 9 days of treatment.






Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2008 by the International Anesthesia Research Society.